Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Nicotine Addiction Vaccines On Phase III Racetrack

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis partners with Cytos on CYT002-NicQb, while Nabi looks to partner NicVax prior to pivotal trials in second half.
Advertisement

Related Content

R&D IN BRIEF
R&D IN BRIEF
Pfizer Taps Into Cytos’ Vaccine Pipeline
Pfizer Taps Into Cytos’ Vaccine Pipeline
Nabi Announces Plans To Evaluate Merger Or Sale Of Firm Under New CEO
Nabi Announces Plans To Evaluate Merger Or Sale Of Firm Under New CEO
Nabi Reports Positive Phase IIb Results For Anti-Smoking Vaccine NicVAX
Nabi Reports Positive Phase IIb Results For Anti-Smoking Vaccine NicVAX
Pfizer Approvals Don’t Quit: Chantix Clears FDA For Smoking Cessation
Pfizer Approvals Don’t Quit: Chantix Clears FDA For Smoking Cessation

Topics

Advertisement
UsernamePublicRestriction

Register

PS065956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel